Leerink Swann Upgrades Regeneron Pharma (REGN) to Outperform; Shares Back to Decent Levels

October 26, 2011 6:57 AM EDT Send to a Friend
Get Alerts REGN Hot Sheet
Price: $427.64 +0.91%

Rating Summary:
    17 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade REGN Now!
Join SI Premium – FREE
Leerink Swann upgraded Regeneron Pharma (NASDAQ: REGN) from Market Perform to Outperform.

Leerink analyst says, "REGN shares continue to be volatile, returning to the levels where we first initiated after reaching the $70s when infections were reported with off-label Avastin. With the 2nd year of VIEW data around the corner representing a significant binary event, we believe current levels offer a decent entry point on a risk-adjusted basis."

"We estimate 50% upside if Eylea beats by >1.5 injections (15% probability); 25% upside if Eylea beats by 0.5-1.5 injections (45% probability); 20% downside if Eylea is as good as Lucentis (30% probability) and 35% downside if Eylea is worse than Lucentis (10% probability)."

For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $57.09 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Upgrades

Add Your Comment